These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27763956)

  • 21. [Differential diagnosis of pancreatic head cancer].
    Kubyshkin VA; Vishnevskiĭ VA; Aĭrapetian AT; Karmazanovskiĭ GG; Kuntsevich GI; Starkov IuG
    Khirurgiia (Mosk); 2000; (11):19-23. PubMed ID: 11220911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
    Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
    Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis.
    Tanţău A; Leucuţa DC; Tanţău M; Boţan E; Zaharie R; Mândruţiu A; Tomuleasa IC
    Dig Dis Sci; 2021 Oct; 66(10):3427-3438. PubMed ID: 33184795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA19-9: the Italian experience.
    Gullo L
    Pancreas; 1994 Nov; 9(6):717-9. PubMed ID: 7846014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of serum CA 19-9 in biliary diseases requires great caution.
    Dorizzi RM; Di Leo A; Guglielmi A; de Manzoni G
    Acta Oncol; 2001; 40(7):877-8. PubMed ID: 11859990
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis.
    Saraswat M; Joenväärä S; Seppänen H; Mustonen H; Haglund C; Renkonen R
    Cancer Med; 2017 Jul; 6(7):1738-1751. PubMed ID: 28573829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
    Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
    Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative Platelet-Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis.
    Rammohan A; Cherukuri SD; Palaniappan R; Perumal SK; Sathyanesan J; Govindan M
    World J Surg; 2015 Sep; 39(9):2323-8. PubMed ID: 25917199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer.
    Ma S; Duan J; Li W; Zhang H; Hou Z
    Artif Cells Nanomed Biotechnol; 2016; 44(2):717-21. PubMed ID: 25472755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.
    Satake K; Takeuchi T; Homma T; Ozaki H
    Pancreas; 1994 Nov; 9(6):703-6. PubMed ID: 7846012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum APRIL, a potential tumor marker in pancreatic cancer.
    Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
    Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.